TYK2

Across TCGA pan-cancer cohorts, TYK2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TYK2 data layer compared with 26 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TYK2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TYK2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where TYK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.868	0.561	.006	22	view →
CCRCC	DFS	Quartile	III,IV	0.443	0.838	.012	4	view →
LSCC	DFS	Median	III,IV	0.944	0.635	.031	3	view →
GBM	OS	Quartile	All	0.589	0.306	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TYK2–PDAC (DFS)

Open the PDAC breakdown →